Singapore, Aug. 22 -- The Health Sciences Authority received information related to the study titled 'Safety, immunogenicity and efficacy of low dose Nivolumab in adults living with HIV on antiretrovi... Read More
Singapore, Aug. 22 -- The Health Sciences Authority received information related to the study titled 'A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study... Read More
Singapore, Aug. 22 -- The Health Sciences Authority received information related to the study titled 'Antigen Targeted T cell therapy for Relapsed/Refractory B cell Lymphomas'. The following are the o... Read More
Singapore, Aug. 22 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More
U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07779174) titled 'Prevalence and Measurement of Delayed Gastric Emptying in Patients Receiving Extracorporeal... Read More
Singapore, Aug. 22 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More
U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07779460) titled 'A Study Comparing Effectiveness of Kesimpta(R) (Ofatumumab) Versus Ocrevus(R) (Ocrelizumab)... Read More
Singapore, Aug. 22 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ... Read More
Singapore, Aug. 22 -- The Health Sciences Authority received information related to the study titled 'A multicenter open-label extension study to evaluate long-term safety and efficacy of QCZ484 in hy... Read More
Singapore, Aug. 22 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascim... Read More